Abstract
Background
Matrix Gla protein (MGP) is a potent calcification inhibitor of the arterial wall. Its activity depends on vitamin K-dependent γ-carboxyglutamate.
Aim
We aimed to investigate the effect of vitamin K1 on MGP levels after 3 months’ supplementation and the relationship between MGP level and vascular calcification.
Patients and methods
A prospective case–control pilot study was conducted overa period of 3 months. The study included 57 long-term hemodialysis patients in stable conditions who were divided into two groups and were compared with 27 healthy age-matched controls. Group I consisted of 28 hemodialysis patients who received vitamin K1 at10 mg three times per week for a successive period of 3 months. Group II consisted of 29 hemodialysis patients who did not receive vitamin K. Group III consisted of 27 healthy participants as controls. The serum level of MGP was measured by radioimmunoassay; in addition, hemoglobin%, parathyroid hormone, calcium, phosphorus, sodium, potassium, alkaline phosphatase, total cholesterol, triglyceride, and carotid intima–media thickness were also measured. Plain radiograph of the abdomen in lateral view was acquired to determine the abdominal aortic calcification score at the start of the study, which was reassessed after 3 months in groups I and II.
Results
We found a significant increase in blood pressure, body mass index (BMI) with elevation in the serum level of MGP in patient groups than control from the start. A significant elevation in MGP level was observed in group I accompanied by a decrease in serum cholesterol level, compared with group II. We did not find any significant change in carotid intima–media thickness or abdominal aortic calcification score in either group after 3 months. There was no significant correlation between elevated MGP level and vascular calcification either. No significant difference was found in other parameters.
Conclusion
Vitamin K supplementation may be essential for End Stage Kidney Disease (ESKD) patients on hemodialysis. Vitamin K can increase the level of MGP and decrease cholesterol level, but its beneficial effect on the vascular bed needs a long-term study.
Article PDF
Similar content being viewed by others
References
Verberckmoes SC, Persy V, Behets GJ, Neven E, Hufkens A, Zebger-Gong H, et al. Uremia-related vascular calcification: more than apatite deposition. Kidney Int 2007; 71:298–303.
Jablonski KL, Chonchol M. Vascular calcification in end-stage renal disease. Hemodial Int 2013; 17:S17–S21
Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology 2007; 12:500–509.
Fusaro M, D’Angelo A, Gallieni M. Consequences of vitamin K2 deficiency in hemodialysis patients. Am J Kidney Dis 2012; 60:168–171.
DiNicolantonio JJ, Bhutani J, O’Keefe HJ. The health benefits of vitamin K. Open Heart 2015; 2:e000300.
Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008; 100:593–603.
Wei FF, Drummen NEA, Schutte AE, Thijs L, Jacobs L, Petit T, et al. Vitamin K dependent protection of renal function in multi-ethnic population studies. EBio Med 2016; 4:162–169.
Schousboe JT, Wilson KE, Hangartner TN. Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. PLoS One 2007; 2:e715.
Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, Sugiura M, Nakagawa K. Conversion of phylloquinone (vitamin K1) into menaquinone-4 (vitamin K2) in mice. Two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem 2008; 283:11270–11279.
Hirota Y, Tsugawa N, Nakagawa K, Suhara Y, Tanaka K, Uchino Y, et al. Menadione (vitamin K3) is a catabolic product of oral phylloquinone (vitamin K1) in the intestine and a circulating precursor of tissue menaquinone-4 (vitamin K2) in rats. J Biol Chem 2013; 288: 33071–33080.
Shearer MJ, Newman P. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res 2014; 55:345–362.
Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25:1629–1633.
Ellen CMC, Schurgers LJ, Uiterwijk HH, Beulens JWJ, Dalmeijer GW, Westerhuis R, et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int 2012; 82:605–610.
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and Dstatusin stages 3–5 chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:590–597.
Stankowiak-Kulpa H, Krzy⊠anowska P, Kozioł L, et al. Vitamin K status in peritoneally dialyzed patients with chronic kidney disease. Acta Biochim Pol 2011; 58:617–620.
Wyskida K, Zakgoła A, Wajda J, Klein D, Witkowicz J, Ficek R, et al. Functional deficiency of vitamin K in hemodialysis patients in Upper Silesia in Poland. Int Urol Nephrol 2016; 48:765–771.
Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 113:S1–130.
Braam LA, Dissel P, Gijsbers BL, Spronk HM, Hamulyák K, Soute BA, et al. Assay for human matrix Gla protein in serum potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000; 20:1257–1261.
Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007; 49:432–439.
Schlieper G, Westenfeld R, Krüger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, et al. Circulating non-phosphorylated carboxylated matrix Gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22:387–395.
Zheng S, Liu Z, Wang D. The efficacy of vitamin K on vascular calcification for chronic renal failure patient receiving dialysis. Int J Clin Exp Med 2016; 9:18092–18097.
Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009; 203:489–493.
Khalil A, Youssef AG. Effect of aerobic exercise, vitamin K and vitamin D on bone metabolism in ovariectomized adult rats. Nat Science 2015; 13:1–11.
Kaesler N, Magdeleyns E, Herfs M, Schettgen T, Brandenburg V, Fliser D, et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 2014; 86:286–293.
Braam LA, Hoeks AP, Brouns F, Hamulyák K, Gerichhausen MJ, Vermeer C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91:373–380.
Shea MK, O’Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89:1799–1807.
Neven E, D’Haese PC. Vascular calcification in chronic renal failure what have we learned from animal studies? Circ Res 2011; 108:249–264.
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarska M, Stefańczyk L, Vermeer C, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3–5. Pol Arch Med Wewn 2015; 125:631–640.
Curiel MD. Action of vitamin K on bone health. Rev Osteoporos Metab Miner 2015; 7:33–38.
Beulens JW, van der ADL, Grobbee DE, Sluijs I, Spijkerman AM, van der Schouw YT. Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care 2010; 33:1699–1705.
European Food Safety Authority (EFSA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2,. Scientific Opinion on the substantiation of a health claim related to monacolin K in SYLVAN BIO red yeast rice and maintenance of normal blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J 2013; 11:3084.
Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59:186–195.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Saad, A.A.E.A., Kenawy, E.M., Elashakr, A.M. et al. Effect of vitamin K1 supplementation on matrix Gla protein level and vascular calcification in hemodialysis patients. Egypt J Intern Med 29, 5–10 (2017). https://doi.org/10.4103/1110-7782.207779
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1110-7782.207779